BeyondSpring Inc.
28 Liberty Street, 39th Floor
New York
New York
10005
United States
142 articles with BeyondSpring Inc.
-
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting
5/27/2022
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced three poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois.
-
BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
4/28/2022
BeyondSpring Inc. announced three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually.
-
BeyondSpring Files 2021 Annual Report on Form 20-F
4/14/2022
BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission on April 14, 2022.
-
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
4/14/2022
BeyondSpring Inc. today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
-
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
4/8/2022
BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022.
-
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company's highest-value activities.
-
BeyondSpring Announces Organizational Streamlining
1/11/2022
BeyondSpring Pharmaceuticals announced an organizational streamlining initiative focused on prioritizing the Company’s highest value business activities, extending its cash runway and preserving long-term sustainability.
-
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
12/30/2021
BeyondSpring Inc. today announced its financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate events.
-
In the CRL, the FDA indicated that the single registrational trial (106 Phase III) did not provide sufficient proof of efficacy to demonstrate benefit.
-
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.
-
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
11/24/2021
BeyondSpring today announced that management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, taking place November 30-December 2, 2021.
-
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
11/10/2021
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative cancer therapeutics, announced the appointment of Mark Santos, RPh, to its Board of Directors, effective immediately.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference
10/20/2021
Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC 70 of 35 nM
-
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination
9/20/2021
BeyondSpring today will have a late-breaking oral presentation at the European Society for Medical Oncology 2021 Congress.
-
Biopharma companies big and small are presenting exciting clinical studies at the European Society for Medical Oncology Congress 2021.
-
BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update- Management to host a call today at 8:00 am ET
9/10/2021
BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate events.
-
BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
9/9/2021
BeyondSpring today announced three poster presentations of new data supporting the combination of plinabulin and G-CSF for the prevention of chemotherapy-induced neutropenia (CIN) at the European Society for Medical Oncology 2021 Congress taking place virtually September 16-21, 2021.
-
BeyondSpring to Participate in the Upcoming September 2021 Conferences
9/8/2021
BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that management will present at and participate in the Morgan Stanley 19th Annual Global Healthcare Conference and R.W. Baird’s 2021 Global Healthcare Conference.
-
BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021
9/7/2021
BeyondSpring Inc. today announced that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time.